Fig. 1: Blocking the transient PT elevation during early-adulthood improves lifespan and healthspan.
From: Early-adulthood spike in protein translation drives aging via juvenile hormone/germline signaling
a PT across ages, determined by (left) 35S-methionine incorporation normalized to protein content (n = 3) and (middle) puromycin incorporation normalized to Ponceau staining (n = 3). Analyses compare PT relative to day 2; one-way ANOVA with Dunnett’s post-hoc test. (Right) in vitro PT assay with luciferase mRNA reporter and fly extracts. Slope of linear part of luciferase activity curve is used to calculate the rate of PT. n = 12/group; one-way ANOVA with Tukey’s post-hoc test. b Early-adulthood PT after ± 1 µM CHX (day 0–10), determined by puromycin incorporation normalized to Ponceau staining. n = 3/group; two-way ANOVA with Sidak correction. c Experimental scheme to transiently manipulate PT in different life stages; 1 µM cyclohexamide (CHX) given to w1118 flies during early-adulthood (day 0–10), late-adulthood (day 40–50), or whole-adulthood. d Early-adulthood (day 0–10) CHX prolongs lifespan just like whole adulthood CHX. Late adulthood (day 40–50) CHX does not alter lifespan. Each sex: n = 250/group; log-rank test. e Early-adulthood (day 0–10) CHX reduces age-related deficits in spontaneous activity. Young=day 12, old=day 50. n = 200/group; two-way ANOVA with Sidak correction. f Early-adulthood (day 0–10) CHX reduces age-related cognitive deficits in olfaction aversion training. Young=day 12, old=day 50. n = 200/group; Chi-square test. g Early-adulthood (day 0–10) CHX prevents age-related deficits in gut-barrier integrity in Smurf assays. n = 250/group; two-way ANOVA with Sidak correction. h (Left) representative images of eggs laid on vials after CHX treatments during early-adulthood (day 0–10). (Right) Early-adulthood CHX impairs egg production at young ages, delays fertility peak, and improves egg production at old ages. n = 100/group; two-way ANOVA with Sidak correction. Data shown as mean ± SD. female data for PT assays and healthspan assays shown here. Male data in Supplementary Fig. 1. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Source data are provided as a Source Data file.
